Early Childhood Care Center. Hospital San Juan de Dios, Seville, Spain.
Human Neuroscience Lab, University Clinic of Psychology, Department of Psychology, Universidad Loyola Andalucia, Dos Hermanas, Seville, Spain.
BMJ Open. 2024 Oct 8;14(10):e083266. doi: 10.1136/bmjopen-2023-083266.
Several studies have highlighted the role of temperament as a relevant construct to understand the wide variability observed in neurodevelopmental disorders (NDDs) such as autism spectrum disorder and attention deficit hyperactivity disorder. Some studies have pointed to temperamental traits such as strained control as possible precursors to the development of these disorders. In addition, how temperament influences high-risk populations, as well as intervention programmes aimed at families, has been investigated.
This paper presents the protocol that will be followed to carry out a systematic review, the objective of which is to know how child temperament is related to the different domains of development in children with NDD or the risk of suffering from it. The search strategy will be implemented in Web of Science (WoS Core Collection), PubMed, ERIC, PsycINFO and Cochrane databases. The risk of bias will be measured by the Newcastle-Ottawa Scale to carry out the integration of the results obtained to synthesis without meta-analysis will be used. This systematic review aims to improve scientific evidence for institutions and professionals and enhance the effectiveness of early care programmes for children with NDD and their families.
No express approval has been sought from any ethics committee because there is no primary data involved and no access to confidential patient information.
CRD42023445173.
多项研究强调了气质作为理解神经发育障碍(NDD)(如自闭症谱系障碍和注意缺陷多动障碍)中观察到的广泛变异性的相关结构的作用。一些研究指出,紧张控制等气质特征可能是这些障碍发展的前兆。此外,还研究了气质如何影响高危人群以及针对家庭的干预计划。
本文介绍了将遵循的系统评价方案,其目的是了解儿童气质与 NDD 儿童或有患病风险的儿童不同发育领域之间的关系。将在 Web of Science(WoS 核心合集)、PubMed、ERIC、PsycINFO 和 Cochrane 数据库中实施搜索策略。将使用纽卡斯尔-渥太华量表来衡量偏倚风险,以进行没有荟萃分析的结果综合。本系统评价旨在为机构和专业人员提供更好的科学证据,并提高 NDD 儿童及其家庭的早期护理计划的效果。
由于没有涉及原始数据,也没有访问机密患者信息,因此没有向任何伦理委员会寻求明确批准。
PROSPERO 注册号: CRD42023445173.